Synthon Hispania, S.L. (full production cycle)

The drug is prescribed for adjuvant therapy in postmenopausal women with early-stage invasive breast cancer (after 2–3 years of tamoxifen therapy), as well as for the treatment of advanced breast cancer in postmenopausal women whose disease progresses after the use of antiestrogens.

Dosage form: tablets, film-coated

ATC: L02BG06